Ocular Therapeutix to Present Data at the American Academy of Optometry Annual Meeting 2021

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Optometry (AAOPT) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.

“The AAOPT is the largest meeting in optometry and works to maintain and enhance excellence in optometric practice, by both promoting research and the dissemination of knowledge,” said Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “We are pleased to have a number of company-sponsored and investigator-initiated presentations at this year’s event highlighting the use of DEXTENZA for the treatment of ocular inflammation and pain as well as for our recently approved label, for the treatment of ocular itching associated with allergic conjunctivitis.”

Presentations / Posters

• Title: Pooled Analysis of a Hydrogel-based Intracanalicular Dexamethasone Insert for the Treatment of Allergic Conjunctivitis
  Presenter: Walter Whitley, OD
  Date / Time: Thursday, November 4^th, 4:30 – 6:30pm ET
  Location: Podium Presentation, Room 253 ABC
• Title: Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness Associated with Allergic Conjunctivitis
  Presenter: Nysha Blender, OD
  Date / Time: Friday, November 5^th, 10:00am – 12:00pm ET
  Location: Poster Board #27, Exhibit Hall B1

Investigator-initiated Trial Presentations

• Title: Comparison of Intracanalicular Dexamethasone Insert to Loteprednol Etabonate Ophthalmic gel 0.38% in Patients with Keratoconus, Allergies and Dry Eye
  Presenter: Jennifer Harthan, OD
  Date / Time: Thursday, November 4^th, 4:30 – 6:30pm ET
  Location: Poster Board #99, Exhibit Hall B1
• Title: Comparison of Preoperative vs Postoperative Dexamethasone Intracanalicular Insert Placement in Controlling Pain & Inflammation following CE/PCIOL.
  Presenter: Lindsey Harris, OD
  Date / Time: Friday, November 5^th, 10:00am – 12:00pm ET
  Location: Poster Board #29, Exhibit Hall B1

All presentations will be available as of November 5^th on the Company’s website (www.ocutx.com, under the Investors tab).

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. In addition to OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, Ocular Therapeutix is currently evaluating OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.